EUVIMEDEUVIMED entdecken
Fallbericht

Durable response to brigatinib in a ROS1 fusion–positive inflammatory myofibroblastic tumor

Gabriela Alamilla-García, Oscar Tahuahua-Flores, Alejandro Soriano-Maya, Enrique Caballé-Pérez, Claudia Haydee Sarai Caro-Sánchez, Dorian Yarih García-Ortega

Cancer Chemotherapy and Pharmacology · 18.04.2026 · 96 (1)

DOI: 10.1007/s00280-026-04886-w ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 18.04.2026. Verfasst von Gabriela Alamilla-García und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico. Hauptthemen laut MEDLINE: Pyrimidines, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Organophosphorus Compounds. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory myofibroblastic tumor is an ultra-rare mesenchymal neoplasm of intermediate malignant potential, characterized by oncogenic rearrangements involving ALK (50–60%), ROS1 (5–10%), and less commonly NTRK3 or RET. We report a 32-year-old woman with an unresectable pulmonary tumor harboring a TFG–ROS1 fusion who achieved a durable partial response to brigatinib, sustained for more than 12 months. Histopathologic evaluation revealed a low-grade spindle-cell neoplasm lacking ALK expression, and genomic profiling identified the actionable fusion. This case highlights how molecular characterization can refine the management of ultra-rare sarcomas, enabling anatomically constrained disease to become targetable and underscoring the role of tumor biology in therapeutic decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesProtein-Tyrosine KinasesProto-Oncogene ProteinsOrganophosphorus CompoundsLung NeoplasmsNeoplasms, Muscle TissueAntineoplastic AgentsHumansFemaleAdultOncogene Proteins, Fusion

Stichwörter der Autor:innen

BrigatinibInflammatory myofibroblastic tumorNext-generation sequencing.ROS1 fusionSarcomaTFG–ROS1 gene fusion

Substanzen

ROS1 protein, humanPyrimidinesProtein-Tyrosine KinasesProto-Oncogene ProteinsOrganophosphorus CompoundsbrigatinibOncogene Proteins, FusionAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico. droscartahuahua@gmail.com.
  • Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Department of Pathology, Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Department of Surgical Oncology (Skin, Soft Tissue and Bone Tumors), Instituto Nacional de Cancerología, Mexico City, Mexico.

Zitieren

APA

Alamilla-García, G., Tahuahua-Flores, O., Soriano-Maya, A., Caballé-Pérez, E., Caro-Sánchez, C. H. S., & García-Ortega, D. Y. (2026). Durable response to brigatinib in a ROS1 fusion–positive inflammatory myofibroblastic tumor. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04886-w

Vancouver

Alamilla-García G, Tahuahua-Flores O, Soriano-Maya A, Caballé-Pérez E, Caro-Sánchez CHS, García-Ortega DY. Durable response to brigatinib in a ROS1 fusion–positive inflammatory myofibroblastic tumor. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04886-w

BibTeX
@article{AlamillaGarca2026,
  author = {Alamilla-García, Gabriela and Tahuahua-Flores, Oscar and Soriano-Maya, Alejandro and Caballé-Pérez, Enrique and Caro-Sánchez, Claudia Haydee Sarai and García-Ortega, Dorian Yarih},
  title = {Durable response to brigatinib in a ROS1 fusion–positive inflammatory myofibroblastic tumor},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04886-w}
}
Kostenlos starten →